APOE and Alzheimer disease: Neuroprotectin D1 (NPD1), a pro-resolving DHA metabolite, was also significantly lower across all AD subgroups (approximately 2–4-fold lower relative levels) except for in females carrying APOE4, who had marginally lower NPD1 levels compared to their respective NCI controls (Fig. 2D).